Concert Wealth Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Concert Wealth Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-13,353	Closed	-$83K	–	595
2014 Q2	$83K	Sell	13,353 -16,500	-55%	-$105K	0.01%	554
2014 Q1	$215K	Buy	29,853 +7,400	+33%	+$43.9K	0.03%	488
2013 Q4	$88K	Buy	+22,453	New	+$86.9K	0.01%	518

Other funds holding NWBO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Concert Wealth Management's NWBO Position: Q3 2014 in Review

Concert Wealth Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2014, closing a stake of 13,353 shares — an estimated $83K sold.

Concert Wealth Management first reported a position in NWBO in Q4 2013 and held it in 3 quarters. The position peaked at $215K in Q1 2014. 71 funds tracked by Wall St. Rank hold NWBO as of Q3 2014.

Concert Wealth Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2014 after selling out during the quarter.
Concert Wealth Management sold 13,353 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2014, an estimated $83K.
Concert Wealth Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 3 quarters.
Concert Wealth Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $215K in Q1 2014.
71 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2014.

Based on Concert Wealth Management's 13F filing for Q3 2014, filed 13 Nov 2014.